Form 4 for VRDN Viridian Therapeutics, Inc.\DE
Accepted 2023-02-03 00:00:00 ET · period of report 2023-02-02 · accession 0000899243-23-003921 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-02-03 | 2023-02-02 | VRDN | Violin Jonathan | CEO, Dir | S - Sale | $36.80 | -50.0K | 430.9K | -10% | -$1.84M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-02 | S | D | 50,000 | $36.80 | 430,905 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $36.1523 to $37.3689. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. |